drugset / Trial / NCT05826574

A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants

NCT05826574

Phase 1 Completed 32 enrolled Insmed Incorporated
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The primary purpose of this study is to assess the effects of rifampin on the PK of brensocatib in Part 1 of the study and to assess the effects of esomeprazole on the PK of brensocatib in Part 2 of the study.

Timeline

Start
2023-05-10
Primary completion
2023-07-16
Completion
2023-07-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Brensocatib Small molecule Oral
Subject Esomeprazole Small molecule 40 mg Oral
Subject Rifampin Small molecule 600 mg Oral

Indications

No indication recorded.